Reduction effect of oral pravastatin on the acute phase response to intravenous zoledronic acid: protocol for a real-world prospective, placebo-controlled trial
Qi Liu(United States Food and Drug Administration), Chunli Song(Peking University), Guohong Du(Peking University), Dongwei Fan(Peking University), Liyuan Tao(Peking University), Haiyan Li(Peking University), Min Zhang(Wuhan Children's Hospital), Gengyu Han(Peking University), Dongyang Liu(Tongji University), Runting Li(Capital Medical University)
Cited by 6
Related Papers
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
|Clinical Cancer Research|2015|532
Current trends in drug metabolism and pharmacokinetics
|Acta Pharmaceutica Sinica B|2019|391
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
|Clinical Cancer Research|2015|377
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
|Clinical Cancer Research|2014|350